Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1B | Q00975 | 1/20 | 0.44 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.44 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.43 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.43 |
| ▸ | CES2 | O00748 | 1/20 | 0.41 |
| ▸ | CES1 | P23141 | 1/20 | 0.41 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 5/20 | 0.38 |
| ▸ | NPC1 | O15118 | 3/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.37 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.35 |
| ▸ | POLB | P06746 | 2/20 | 0.35 |
| ▸ | PKM | P14618 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 4/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12708959 | 1.00 | CACNA1B (0.44) | CACNA1BAPBA1CYP11B1CYP11B2CES2 | |
| SCHEMBL1554026 | 1.00 | CACNA1B (0.44) | CACNA1BAPBA1CYP11B1CYP11B2CES2 | |
| SCHEMBL13071294 | 0.82 | CES2 (0.38) | CES2CES1L3MBTL1RAB9ANPC1 | |
| SCHEMBL12709046 | 0.81 | CYP11B1 (0.50) | CYP11B1CYP11B2CES2CES1NAPRT | |
| SCHEMBL1553298 | 0.81 | CYP11B1 (0.50) | CYP11B1CYP11B2CES2CES1NAPRT | |
| SCHEMBL1553299 | 0.81 | CYP11B1 (0.50) | CYP11B1CYP11B2CES2CES1NAPRT | |
| SCHEMBL1554508 | 0.78 | TP53 (0.48) | CES2CES1RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL1554509 | 0.78 | TP53 (0.48) | CES2CES1RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL23832211 | 0.77 | NAPRT (0.54) | CYP11B1CYP11B2NAPRTL3MBTL1RAB9A | |
| SCHEMBL1553772 | 0.76 | TDP1 (0.56) | CYP11B1CYP11B2CES2CES1NAPRT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1439175-B1 | PYRIMIDINE COMPOUND AND MEDICINAL COMPOSITION THEREOF | EISAI R&D MAN CO LTD (JP) | 2011-04-27 | — | — | EP | disclosed |
| EP-2246344-A1 | Pyrimidine compounds and medicinal composition thereof | Eisai R&D Management Co., Ltd. (JP) | 2010-11-03 | — | — | EP | disclosed |
| US-7767812-B2 | Crystals of pyrimidine compound and process for producing the same | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-08-03 | — | — | US | disclosed |
| EP-2210889-A1 | Process for producing pyrimidine compound | Eisai R&D Management Co., Ltd. (JP) | 2010-07-28 | — | — | EP | disclosed |
| US-7538117-B2 | Crystalline and amorphous pyrimidine compounds and processes for preparing pyrimidine compounds | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-05-26 | — | — | US | disclosed |
| US-20090111986-A1 | NOVEL CRYSTALS OF PYRIMIDINE COMPOUND AND PROCESS FOR PRODUCING THE SAME | HARADA HITOSHI | 2009-04-30 | — | — | US | disclosed |
| US-20090030023-A1 | PYRIMIDINE COMPOUNDS AND MEDICINAL COMPOSITION THEREOF | HARADA HITOSHI | 2009-01-29 | — | — | US | disclosed |
| US-7396836-B2 | Pyrimidine compound and medicinal composition thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2008-07-08 | — | — | US | disclosed |
| EP-1862463-A1 | PYRIMIDINE COMPOUND CRYSTAL OR AMORPHOUS FORM AND PROCESS FOR PRODUCING THE SAME | Eisai R&D Management Co., Ltd. (JP) | 2007-12-05 | — | — | EP | disclosed |
| US-20070078151-A1 | Crystalline and amorphous pyrimidine compounds and processes for preparing pyrimidine compounds | EISAI CO., LTD. (JP) | 2007-04-05 | — | — | US | disclosed |
| US-20050004149-A1 | Pyrimidine compound and medicinal composition thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2005-01-06 | — | — | US | disclosed |
| EP-1439175-A1 | PYRIMIDINE COMPOUND AND MEDICINAL COMPOSITION THEREOF | Eisai Co., Ltd. (JP) | 2004-07-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090030023-A1 | PYRIMIDINE COMPOUNDS AND MEDICINAL COMPOSITION THEREOF | CBR3, AHR, HCCS | CACNA1B 3326/4885APBA1 1918/4885CYP11B1 110/4885 |
| US-20070078151-A1 | Crystalline and amorphous pyrimidine compounds and processes for preparing pyrimidine compounds | UMPS, TYMP, UPP1 | CACNA1B 3221/4885APBA1 727/4885CYP11B1 4504/4885 |
| US-20050004149-A1 | Pyrimidine compound and medicinal composition thereof | ADORA2B, ADORA2A, ADORA3 | CACNA1B 2106/4885APBA1 1512/4885CYP11B1 209/4885 |
| US-20090111986-A1 | NOVEL CRYSTALS OF PYRIMIDINE COMPOUND AND PROCESS FOR PRODUCING THE SAME | UMPS, P2RX5, APC | CACNA1B 2175/4885APBA1 1040/4885CYP11B1 4415/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.